Platforms
Our modular ADC platforms are generating potential first and best in class assets, including novel proprietary payloads, linker and drug conjugation, and improved targeting. This includes clinically validated MOAs, dual payloads, and tumor specific release. These platforms are enabling us to efficiently engineer ADCs that tackle cancers that current therapies cannot, with a multiplier effect of technology platforms delivering solutions beyond today’s therapeutic boundaries.
We are open to exploring strategic collaborations, licensing opportunities, and co-development partnerships across our platforms and proprietary programs.
Novel Payload Approaches
A first-in-class antifolate payload leveraging a clinically validated mechanism of action not previously used in targeted therapy, designed to overcome resistance to existing ADCs and expand treatment options for patients facing difficult-to-treat cancers.
A first-in-class immunostimulatory phosphonate payload designed to address a critical need for patients who do not respond to immunotherapy, powering tumor-selective activation of γδ T cells through MHC-independent recognition of cancer cells.
Masking Technology
A best-in-class steric masking platform providing a universal solution to reduce off-tumor toxicity, designed to improve the therapeutic index of antibody-based therapies.
Pipeline
Our pipeline reflects over 20 years of ADC expertise across research, lead identification, preclinical and clinical development, and manufacturing, all focused on enabling ADCs to fulfill their therapeutic potential.
Publications & Presentations
Novel developments are regularly published in highly ranked peer-reviewed journals.
